Working… Menu

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02632708
Recruitment Status : Active, not recruiting
First Posted : December 17, 2015
Last Update Posted : March 23, 2021
Celgene Corporation
Information provided by (Responsible Party):
Agios Pharmaceuticals, Inc.